These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28104232)

  • 41. Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?
    Okun MS; Weintraub D
    Mov Disord; 2013 Dec; 28(14):1915-9. PubMed ID: 24243803
    [No Abstract]   [Full Text] [Related]  

  • 42. Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease.
    Lizarraga KJ; Fox SH; Strafella AP; Lang AE
    Clin Geriatr Med; 2020 Feb; 36(1):105-118. PubMed ID: 31733691
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impulse Control Disorders in Parkinson's Disease.
    Weintraub D; Mamikonyan E
    Am J Psychiatry; 2019 Jan; 176(1):5-11. PubMed ID: 30848949
    [No Abstract]   [Full Text] [Related]  

  • 44. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease.
    Kimber TE; Thompson PD; Kiley MA
    J Clin Neurosci; 2008 Feb; 15(2):205-8. PubMed ID: 18068992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Disinhibitory abnormal behavior induced by treatment of Parkinson disease].
    Fujimoto K
    Brain Nerve; 2012 Apr; 64(4):373-83. PubMed ID: 22481510
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome without impulse control disorder or drug abuse.
    Shimo Y; Nakajima A; Hattori N
    Neurol Sci; 2015 Jun; 36(6):1021-3. PubMed ID: 25362251
    [No Abstract]   [Full Text] [Related]  

  • 47. Binge eating in Parkinson's disease: prevalence, correlates and the contribution of deep brain stimulation.
    Zahodne LB; Susatia F; Bowers D; Ong TL; Jacobson CE; Okun MS; Rodriguez RL; Malaty IA; Foote KD; Fernandez HH
    J Neuropsychiatry Clin Neurosci; 2011; 23(1):56-62. PubMed ID: 21304139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Multicenter Comparative Study of Impulse Control Disorder in Latin American Patients With Parkinson Disease.
    Ramírez Gómez CC; Serrano Dueñas M; Bernal O; Araoz N; Sáenz Farret M; Aldinio V; Montilla V; Micheli F
    Clin Neuropharmacol; 2017; 40(2):51-55. PubMed ID: 28288482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Suicide without depression after withdrawal of a dopamine agonist in a patient with Parkinson's disease.
    Flament M; Loas G; Godefroy O; Krystkowiak P
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):E32. PubMed ID: 22231340
    [No Abstract]   [Full Text] [Related]  

  • 50. Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up.
    Houeto JL; Mesnage V; Welter ML; Mallet L; Agid Y; Bejjani BP
    Neurology; 2003 Jan; 60(1):154-5; author reply 154-5. PubMed ID: 12530402
    [No Abstract]   [Full Text] [Related]  

  • 51. Hypersexuality and compulsive over-eating associated with transdermal dopamine agonist therapy.
    Hinnell C; Hulse N; Martin A; Samuel M
    Parkinsonism Relat Disord; 2011 May; 17(4):295-6. PubMed ID: 21300562
    [No Abstract]   [Full Text] [Related]  

  • 52. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs.
    Moore TJ; Glenmullen J; Mattison DR
    JAMA Intern Med; 2014 Dec; 174(12):1930-3. PubMed ID: 25329919
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
    Joutsa J; Martikainen K; Vahlberg T; Kaasinen V
    Parkinsonism Relat Disord; 2012 Dec; 18(10):1079-83. PubMed ID: 22784693
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.
    Payer DE; Guttman M; Kish SJ; Tong J; Strafella A; Zack M; Adams JR; Rusjan P; Houle S; Furukawa Y; Wilson AA; Boileau I
    Mov Disord; 2015 Feb; 30(2):160-6. PubMed ID: 25641350
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Case Report.
    Luchsinger WT; Gambhir N; DeMoss D
    Prim Care Companion CNS Disord; 2018 Apr; 20(2):. PubMed ID: 29701928
    [No Abstract]   [Full Text] [Related]  

  • 56. Infusion Therapies and Development of Impulse Control Disorders in Advanced Parkinson Disease: Clinical Experience After 3 Years' Follow-up.
    Todorova A; Samuel M; Brown RG; Chaudhuri KR
    Clin Neuropharmacol; 2015; 38(4):132-4. PubMed ID: 26166238
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuropsychiatric effects of Parkinson's disease treatment.
    Aarons S; Peisah C; Wijeratne C
    Australas J Ageing; 2012 Sep; 31(3):198-202. PubMed ID: 22950594
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment-induced Delusions of Infestation Associated with Increased Brain Dopamine Levels.
    Fowler E; Maderal A; Yosipovitch G
    Acta Derm Venereol; 2019 Mar; 99(3):327-328. PubMed ID: 30460371
    [No Abstract]   [Full Text] [Related]  

  • 59. Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up.
    Lang AE; Kleiner-Fisman G; Saint-Cyr JA; Miyasaki J; Lozano A
    Neurology; 2003 Jan; 60(1):154-5; author reply 154-5. PubMed ID: 12525751
    [No Abstract]   [Full Text] [Related]  

  • 60. [Impulse control disorders associated with dopaminergic agonists in Parkinson's disease. Case report].
    Gamboa Arango A; Bernal Bernal MT; Duaso Magaña E
    Rev Esp Geriatr Gerontol; 2016; 51(5):304-5. PubMed ID: 27016028
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.